期刊
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
卷 24, 期 1, 页码 19-25出版社
JAPAN ATHEROSCLEROSIS SOC
DOI: 10.5551/jat.RV16004
关键词
Statin; Racial differences; Asian; Westerner
资金
- Takeda Pharmaceutical
- Bristol-Myers Squibb
- Nippon Boehringer Ingelheim
- Astellas Pharma
- Novartis Pharma
- MSD
- Sanofi-Aventis
- Otsuka Pharmaceutical
- Dainippon Sumitomo Pharma
- Pfizer
- Kowa Pharmaceutical
- Shionogi
- AstraZeneca
- Teijin
- Morinaga Milk Industry
Statin treatment to reduce low-density lipoprotein cholesterol (LDL-C) is associated with the prevention of cardiovascular events in Western patients. Similar results have been reported in studies conducted in Japan. However, the dose of statins and the degree of LDL-C reduction achieved with statins are different between Asian and Western patients. In addition, there are limited data regarding racial differences in response to statins. In this review, racial differences between Asians and Westerners in response to statins are described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据